Resultados: 5

    Guideline No 428: management of dichorionic twin pregnancies

    J. obstet. gynaecol. Can; 44 (7), 2022
    To review evidence-based recommendations for the management of dichorionic twin pregnancies. Pregnant women with a dichorionic twin pregnancy. Implementation of the recommendations in this guideline may improve the management of twin pregnancies and reduce neonatal and maternal morbidity and mortality. P...

    Guideline No 427: folic acid and multivitamin supplementation for prevention of folic acid–sensitive congenital anomalies

    J. obstet. gynaecol. Can; 44 (6), 2022
    To provide updated guidance on pre-conception folic acid and multivitamin supplementation for primary and secondary (recurrence) prevention of neural tube defects and other folate-sensitive congenital anomalies. Women aged 12-45 years who could become pregnant should be aware of the risk of serious birth...

    Guideline No. 410: prevention, screening, diagnosis, and pregnancy Management for fetal neural tube defects

    J. obstet. gynaecol. Can; 43 (1), 2021
    This revised guideline is intended to provide an update on the genetic aspects, prevention, screening, diagnosis, and management of fetal neural tube defects. Target population: Women who are pregnant or may become pregnant. Neural tube defect screening should be offered to all pregnant women. For preven...

    Guideline No. 402: diagnosis and management of placenta previa

    J. obstet. gynaecol. Can; 42 (7), 2020
    To summarize the current evidence and to make recommendations for diagnosis and classification of placenta previa and for managing the care of women with this diagnosis. To manage in hospital or as an outpatient and to perform a cesarean delivery preterm or at term or to allow a trial of labour when a di...

    Guideline No. 398: progesterone for prevention of spontaneous preterm birth

    J. obstet. gynaecol. Can; 42 (6), 2020
    To assess the benefits and risks of progesterone therapy for women at increased risk of spontaneous preterm birth (SPB) and to make recommendations for the use of progesterone to reduce the risk of SPB and improve postnatal outcomes. To administer or withhold progesterone therapy for women deemed to be a...